#1 Clinical Trials Search in Europe

Azd5492

Clinical trials are investigating Azd5492 in adults with B-cell blood cancers. These studies aim to learn whether Azd5492 is safe and whether it may work alone or with other cancer treatments. The trial data shown here focuses on people with relapsed or refractory B-cell malignancies.

Table of contents

Trial overview

This authorised study is testing Azd5492 in adults with B-cell malignancies, which are cancers that start in B cells, a type of white blood cell.[1] The trial title says the study is looking at whether Azd5492 is safe and whether it works when given alone and in combination with other cancer treatments.[1]

The brief summary says the main objective is to assess the safety and tolerability of Azd5492 as monotherapy or in combination with other anticancer agents in participants with relapsed or refractory B-cell malignancies.[1] Relapsed means the cancer came back after treatment, and refractory means it did not respond well to treatment.[1]

Who can join

The study is for adults with B-cell blood cancers.[1] The trial data also says participants have relapsed or refractory disease, so the cancer has either returned or has not improved enough after previous treatment.[1]

No more detailed age, cancer subtype, or prior treatment rules are given in the trial data provided.[1]

What is being measured

The main outcomes are focused on safety.[1] Researchers will look for dose-limiting toxicities (DLTs), which are side effects serious enough to limit treatment, and they will also track the incidence and severity of adverse events (AEs), adverse events of special interest (AESIs), and serious adverse events (SAEs).[1]

The study will also check for SAEs or AEs that lead to stopping Azd5492, plus clinically significant changes in vital signs and abnormal laboratory parameters.[1] Vital signs are basic body checks like blood pressure and pulse, while laboratory parameters are results from blood or other tests.[1]

Trial phase and design

This is a Phase 1 study, which is an early clinical trial stage.[1] Phase 1 studies mainly aim to understand safety and tolerability, and they may also give early clues about whether a treatment could help.[1]

The study is listed as interventional, which means researchers are actively giving the treatment and observing the results.[1] The enrollment number is 176, which is the planned number of participants in the study.[1]

The intervention listed in the trial data is AZD5492 given by subcutaneous administration, which means under the skin.[1]

What this means for patients

For patients, this trial is mainly about learning whether Azd5492 can be used safely in people with hard-to-treat B-cell blood cancers.[1] The study is also exploring whether Azd5492 may be given by itself or together with other cancer treatments.[1]

Because this is an early-phase study, the main focus is not yet on proving long-term benefit, but on understanding safety, side effects, and early treatment signals.[1]

Trial ID Phase Condition studied Status Enrollment
2024-511099-34-00 Phase 1 B-cell malignancies Authorised 176

FAQ

  • What is being studied in Azd5492 clinical trials? The trials are studying whether Azd5492 is safe and whether it may work in adults with B-cell blood cancers. Some parts of the study also test Azd5492 together with other anticancer treatments.
  • Who can take part in these trials? The trial is for adults with relapsed or refractory B-cell malignancies. This means the cancer has come back or did not respond well to earlier treatment.
  • What phase is the Azd5492 trial? The trial is Phase 1. Phase 1 studies are early trials that mainly look at safety, tolerability, and signs of how the treatment behaves in people.
  • What conditions are being studied? The study is focused on B-cell malignancies, which are cancers of B cells, a type of white blood cell. The trial data does not list a more specific cancer type.
  • What outcomes are researchers measuring? Researchers are checking for dose-limiting toxicities, side effects, serious side effects, and whether treatment must be stopped. They are also watching vital signs and lab test results for important changes.

Ongoing Clinical Trials on Azd5492

  • Study on the Safety and Effectiveness of AZD5492 Alone or with Other Treatments for Adults with Relapsed or Refractory B-Cell Blood Cancers

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Germany Italy Spain

Glossary

  • B-cell malignancies: Cancers that start in B cells, which are a type of white blood cell.
  • Relapsed or refractory (R/R): Relapsed means the cancer came back after treatment. Refractory means it did not respond well to treatment.
  • Phase 1: An early stage of clinical testing that mainly checks safety and tolerability.
  • Interventional study: A study where researchers give a treatment and then watch what happens.
  • Monotherapy: Treatment given by itself, without other cancer drugs.
  • Combination therapy: Treatment used together with one or more other medicines.
  • Dose-limiting toxicities (DLTs): Side effects serious enough to limit how much treatment can be given.
  • Adverse events (AEs): Any unwanted medical problems that happen during a study.
  • Serious adverse events (SAEs): Side effects or medical problems that are severe and may need urgent care.
  • Vital signs: Basic body checks such as blood pressure, pulse, temperature, and breathing rate.
  • Laboratory parameters: Results from blood or other lab tests that help show how the body is doing.

References

  1. https://clinicaltrials.gov/study/2024-511099-34-00